Global Cancer Immunotherapy Market Size By Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors), By Application (Lung Cancer, Breast Cancer), By Region, And Segment Forecasts, 2023 to 2032

The Global Cancer Immunotherapy Market was valued at USD 118.3 billion in 2023 and is expected to reach USD 280.1 billion by 2031, expanding at a CAGR of 11.2% during the forecast period of 2023–2031. This robust growth is driven by the increasing prevalence of various cancers, rising awareness of advanced treatment options, and growing investments in biopharmaceutical research. Cancer immunotherapy—also known as biologic therapy—uses the body's immune system to fight cancer and has become a cornerstone in modern oncology, offering improved survival rates with fewer side effects than conventional treatments.

Drivers:

1. Rising Cancer Incidence Worldwide:

The increasing global burden of cancer is one of the primary growth drivers. According to WHO, cancer is a leading cause of death globally, and the need for effective therapies like immunotherapy is rising proportionally.

2. Advancements in Immuno-Oncology Research:

Ongoing innovations in checkpoint inhibitors, monoclonal antibodies, and cell-based therapies such as CAR-T have significantly boosted the efficacy and adoption of immunotherapies.

3. Favorable Government and Regulatory Support:

Global regulatory bodies like the FDA and EMA are streamlining the approval processes for cancer immunotherapies, accelerating market entry and boosting patient access.

Restraints:

1. High Treatment Costs:

The elevated cost of cancer immunotherapies remains a major barrier, limiting accessibility, particularly in low- and middle-income countries.

2. Limited Patient Response and Resistance:

Not all patients respond to immunotherapy. Issues such as tumor microenvironment and immunotherapy resistance may reduce treatment efficacy, posing clinical challenges.

Opportunity:

1. Personalized Cancer Vaccines and Combination Therapies:

Emerging technologies in genomics and bioinformatics are enabling personalized immunotherapy approaches, enhancing patient response. Additionally, combination therapies using immunotherapy with chemotherapy or radiotherapy are showing promising results.

2. Expansion in Emerging Markets:

The rising healthcare infrastructure in Asia-Pacific, Latin America, and the Middle East provides untapped growth opportunities, particularly with government focus on oncology healthcare and foreign investments.

Market by System Type Insights:

By system type, the Checkpoint Inhibitors segment dominated the market in 2023, driven by their proven efficacy in treating multiple cancers, including melanoma, lung, and bladder cancers. Meanwhile, CAR-T cell therapy is expected to witness the highest growth during the forecast period due to its personalized approach and increasing FDA approvals for new indications.

Market by End-use Insights:

Hospitals led the market in 2023, accounting for over 50% of global revenue, due to their ability to provide advanced cancer therapies and inpatient care facilities. Cancer research institutes are also contributing significantly to market growth, driven by rising clinical trials and R&D investments in immuno-oncology.

Market by Regional Insights:

North America dominated the global cancer immunotherapy market in 2023, supported by strong R&D activities, high cancer prevalence, and a well-established healthcare system. Asia-Pacific is expected to register the fastest CAGR during the forecast period due to increasing healthcare investments, rising cancer cases, and growing adoption of advanced cancer treatments in countries like China, India, and Japan.

Competitive Scenario:

Key players operating in the Global Cancer Immunotherapy Market include Bristol-Myers Squibb, Merck & Co., Inc., Roche Holding AG, Novartis AG, AstraZeneca plc, Pfizer Inc., Amgen Inc., Gilead Sciences, Inc., Eli Lilly and Company, and AbbVie Inc. These companies are focused on expanding their immuno-oncology pipelines, strategic collaborations, and new product launches.

Recent Developments:

In 2023, Merck’s Keytruda received FDA approval for an expanded indication in early-stage triple-negative breast cancer.

In 2024, Bristol-Myers Squibb announced promising Phase III results for its next-gen checkpoint inhibitor in non-small cell lung cancer.

In 2025, Roche partnered with a biotech firm to develop AI-driven biomarkers to enhance immunotherapy response prediction.

Scope of Work – Global Cancer Immunotherapy Market

Report Metric Details

Market Size (2023) USD 118.3 billion

Projected Market Size (2031) USD 280.1 billion

CAGR (2023–2031) 11.2%

Market Segments By System Type (Checkpoint Inhibitors, Monoclonal Antibodies, CAR-T Cell Therapy), By End-use (Hospitals, Cancer Research Institutes, Specialty Clinics)

Growth Drivers Increasing cancer prevalence, immunotherapy advancements, regulatory support

Opportunities Personalized immunotherapy, emerging markets, combination therapy expansion

Key Market Developments:

August 2023: Merck expanded clinical trials for its mRNA-based personalized cancer vaccine in collaboration with Moderna.

February 2024: Gilead Sciences acquired a biotech startup specializing in next-gen T-cell therapies.

March 2025: Novartis launched a digital companion app to support patients undergoing CAR-T therapy.

FAQs:

1) What is the current market size of the Global Cancer Immunotherapy Market?

The market was valued at USD 118.3 billion in 2023.

2) What is the major growth driver of the Global Cancer Immunotherapy Market?

The primary driver is the increasing prevalence of cancer and rapid advancements in immunotherapy research.

3) Which is the largest region during the forecast period in the Global Cancer Immunotherapy Market?

North America holds the largest market share due to robust healthcare infrastructure and advanced oncology research.

4) Which segment accounted for the largest market share in the Global Cancer Immunotherapy Market?

Checkpoint Inhibitors led the market in 2023 due to widespread clinical success across various cancers.

5) Who are the key market players in the Global Cancer Immunotherapy Market?

Key players include Merck & Co., Roche, Bristol-Myers Squibb, Pfizer, AstraZeneca, and Novartis.

Let me know if you'd like this description exported as a Word document or formatted for a specific platform.